Evaluation of Mdh1 Protein as an Antigenic Candidate for a Vaccine against Candidiasis

Access this Article

Search this Article

Author(s)

    • SHIBASAKI SEIJI
    • General Education Center, Hyogo University of Health Sciences|Graduate School of Pharmacy, Hyogo University of Health Sciences
    • AOKI WATARU
    • Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University
    • KARASAKI MIKI
    • General Education Center, Hyogo University of Health Sciences
    • UEDA MITSUYOSHI
    • Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University

Abstract

<I>Candida albicans</I> malate dehydrogenase (Mdh1p) has been screened by previous proteome studies as a candidate for a vaccine against candidiasis. In this study, recombinant Mdh1 protein with a His-tag was produced in <I>Escherichia coli</I> and evaluated as an immunogenic protein against candidiasis. Mdh1p was administrated to mice by two methods subcutaneous injection and intranasal administration before challenging them with a lethal dose of <I>C. albicans</I>. After vaccination of Mdh1p, antibody responses were observed. To evaluate the vaccination effect of Mdh1p, survival tests were performed after 35 d. Although all control mice died within 24 d or 25 d, 100% and 80% of mice survived with subcutaneous and intranasal administration, respectively. Therefore, our results indicate that, among <I>C. albicans</I> antigens examined thus far, Mdh1p is currently the most effective antigen for use as a vaccine for <I>C. albicans</I>.

Journal

  • Biocontrol Science

    Biocontrol Science 19(1), 51-55, 2014

    The Society for Antibacterial and Antifungal Agents, Japan

Codes

  • NII Article ID (NAID)
    130003395463
  • Text Lang
    ENG
  • ISSN
    1342-4815
  • Data Source
    J-STAGE 
Page Top